SUBSCRIBE
SUBSCRIBE
News   Drug Development

Sanofi-Aventis (France) Drug Jevtana Boosts Prostate Cancer Survival 30%; Impresses in Phase III Clinical Trial

March 4, 2010 | 
1 min read
Reuters -- Sanofi-Aventis's experimental chemotherapy drug Jevtana increases survival by 30 percent in men with prostate cancer whose tumours no longer respond to standard treatment, according to new research.
Clinical research Phase III
Sanofi (France)
MORE ON THIS TOPIC
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
stairs going upward
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
January 12, 2026
 · 
6 min read
 · 
Heather McKenzie